| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Dixanthogen does not have a single, well-defined primary drug target. Its mechanism of action is not fully understood but is believed to involve the inhibition of enzymes and the modulation of signal transduction pathways. As an ectoparasiticide, its action involves interfering with the cell membrane structure and function of parasites on the body surface, leading to metabolic disruption and death. The compound's ability to form stable complexes with metal ions enhances the hydrophobic properties of minerals, a property leveraged in industrial applications.
|
|---|---|
| ln Vitro |
Dixanthogen has demonstrated various biological activities in vitro. It exhibits antimicrobial, antitumor, and anti-inflammatory effects. In vitro solubility data shows that it is soluble in DMSO and ethanol at concentrations up to 48 mg/mL. The compound is used in research exploring new ectoparasiticide development, mechanisms of parasite drug resistance, and pharmacodynamic dose evaluation.
|
| ln Vivo |
In vivo, dixanthogen functions as an ectoparasiticide, applied to control external parasites. Its in vivo applications are primarily in veterinary and agricultural contexts rather than human medicine. The compound's low toxicity compared to other xanthates makes it a preferred choice in certain applications. It has been applied in experimental animal systems for efficacy and dose evaluation studies.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for dixanthogen are not extensively documented. Given its proposed mechanism involving enzyme inhibition, potential assays could involve studying its interaction with key enzymes in parasites or its ability to modulate signal transduction pathways. Binding affinity could be determined using surface plasmon resonance or isothermal titration calorimetry. The compound's ability to inhibit specific enzyme activities could be measured using spectrophotometric or fluorometric methods.
|
| Cell Assay |
Cell-based experiments with dixanthogen would involve treating parasite or pest cell cultures to assess its biological activity and mechanism of action. Cells would be incubated with varying concentrations of the compound, and effects on cell viability, membrane integrity, or metabolic activity would be measured using standard assays such as MTT or LDH release assays. Such studies are fundamental to understanding its ectoparasiticidal effects and exploring potential antimicrobial or antitumor activities.
|
| Animal Protocol |
In vivo animal studies for dixanthogen typically involve its application as an ectoparasiticide in veterinary settings or experimental animal models. Efficacy is measured by parasite or pest mortality. The compound has been used in research exploring new ectoparasiticide development and pharmacodynamic dose evaluation. Toxicological studies in animals have been conducted to assess its safety profile.
|
| ADME/Pharmacokinetics |
Dedicated pharmacokinetic data for dixanthogen is limited. The compound is known to have low toxicity compared to other xanthates. In vitro and in vivo formulation data indicates it can be prepared in various solvents, including DMSO, ethanol, and mixtures with PEG300 and Tween80 for administration. Its chemical properties suggest it can be absorbed and distributed in biological systems, but detailed PK parameters such as half-life, volume of distribution, and clearance are not well-characterized in the literature.
|
| Toxicity/Toxicokinetics |
The toxicological profile of dixanthogen is characterized by relatively low toxicity compared to other xanthates. It is considered an endocrine disruptor. Acute toxicity data indicates it can be lethal at very low doses for some organisms, classifying it as a highly acutely toxic pesticide. It has been targeted for global phaseout under the Stockholm Convention for Persistent Organic Pollutants. In industrial settings, it is considered a hazardous substance requiring appropriate safety precautions.
|
| Additional Infomation |
Dixanthogen acid is a thiocarbonyl compound.
Dixanthogen is an ectoparasiticide and an industrial chemical used in mineral flotation processes. It is not approved for human therapeutic use. The compound serves as a valuable research tool for studying pesticide mechanisms, parasite drug resistance, and developing new ectoparasiticides. Its ability to reflect residual xanthate levels in water makes it useful in environmental monitoring. |
| Molecular Formula |
C6H10O2S4
|
|---|---|
| Molecular Weight |
242.384
|
| Exact Mass |
241.956
|
| CAS # |
502-55-6
|
| PubChem CID |
10404
|
| Appearance |
Colorless to light yellow liquid（Density：1.352 g/cm3）
|
| Density |
0.94 g/mL at 25 °C(lit.)
|
| Boiling Point |
134 °C2 mm Hg(lit.)
|
| Flash Point |
>230 °F
|
| Index of Refraction |
n20/D 1.479(lit.)
|
| LogP |
3.01
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
12
|
| Complexity |
142
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(SSC(OCC)=S)=S
|
| InChi Key |
FVIGODVHAVLZOO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H10O2S4/c1-3-7-5(9)11-12-6(10)8-4-2/h3-4H2,1-2H3
|
| Chemical Name |
O-ethyl (ethoxycarbothioyldisulfanyl)methanethioate
|
| Synonyms |
BRN-1781595; BRN 1781595; Dixanthogen
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1031.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (25.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (25.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 6.25 mg/mL (25.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1258 mL | 20.6288 mL | 41.2575 mL | |
| 5 mM | 0.8252 mL | 4.1258 mL | 8.2515 mL | |
| 10 mM | 0.4126 mL | 2.0629 mL | 4.1258 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
